Arcturus Therapeutics, based in San Diego, has proprietary enabling technologies: (i) LUNAR lipid-mediated delivery, (ii) self-transcribing and replicating mRNA (STARR) technology, and (iii ...

CARGO Therapeutics, Inc. announced the discontinuation of its FIRCE-1 Phase 2 clinical study of firicabtagene autoleucel (firi-cel) for large B-cell lymphoma due to safety concerns and ...

Looking more longer term, this funding will also allow us to scale-up development - an important step towards larger Phase 2 clinical trials.” “We are thrilled to support Valo Therapeutics in ...

Outlook Therapeutics, Inc. has announced the participation of Dr. Jennifer Kissner, Senior Vice President of Clinical Development, in a Virtual Investor segment discussing the 12-week safety and ...